Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Eur J Clin Microbiol Infect Dis ; 36(9): 1595-1611, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28397100

RESUMEN

Risk assessment of central nervous system (CNS) infection patients is of key importance in predicting likely pathogens. However, data are lacking on the epidemiology globally. We performed a multicenter study to understand the burden of community-acquired CNS (CA-CNS) infections between 2012 and 2014. A total of 2583 patients with CA-CNS infections were included from 37 referral centers in 20 countries. Of these, 477 (18.5%) patients survived with sequelae and 227 (8.8%) died, and 1879 (72.7%) patients were discharged with complete cure. The most frequent infecting pathogens in this study were Streptococcus pneumoniae (n = 206, 8%) and Mycobacterium tuberculosis (n = 152, 5.9%). Varicella zoster virus and Listeria were other common pathogens in the elderly. Although staphylococci and Listeria resulted in frequent infections in immunocompromised patients, cryptococci were leading pathogens in human immunodeficiency virus (HIV)-positive individuals. Among the patients with any proven etiology, 96 (8.9%) patients presented with clinical features of a chronic CNS disease. Neurosyphilis, neurobrucellosis, neuroborreliosis, and CNS tuberculosis had a predilection to present chronic courses. Listeria monocytogenes, Staphylococcus aureus, M. tuberculosis, and S. pneumoniae were the most fatal forms, while sequelae were significantly higher for herpes simplex virus type 1 (p < 0.05 for all). Tackling the high burden of CNS infections globally can only be achieved with effective pneumococcal immunization and strategies to eliminate tuberculosis, and more must be done to improve diagnostic capacity.


Asunto(s)
Infecciones del Sistema Nervioso Central/epidemiología , Infecciones Comunitarias Adquiridas/epidemiología , Vigilancia de la Población , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Infecciones del Sistema Nervioso Central/etiología , Infecciones del Sistema Nervioso Central/mortalidad , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/mortalidad , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Estudios Retrospectivos , Adulto Joven
2.
HIV Med ; 16(2): 132-6, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25124291

RESUMEN

OBJECTIVES: Emtricitabine/tenofovir/rilpivirine as a single-tablet regimen (STR) is widely used without licence in treatment-experienced patients. The purpose of this retrospective observational study was to assess viral suppression of ART-experienced patients switching to STR. METHODS: We assessed 131 pretreated patients switching to STR with HIV RNA <400 HIV-1 RNA copies/mL. The primary outcome measure was the proportion of patients at week 24 with HIV RNA <40 copies/mL. RESULTS: By week 24, eight patients had stopped STR: four because of adverse events and four for other reasons. Three virological failures were observed; among these, at least one patient developed cross-resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs), in particular with the E138K pattern. In intent-to-treat analysis, 92% of participants (120 of 131) achieved HIV RNA <40 copies/mL. Only grade 1 to 2 adverse events were observed, mainly consisting of increased liver enzymes (n=33). Systemic exposure to rilpivirine was above the usually observed steady-state levels for the 18 measurements assessed. CONCLUSIONS: Efficacy and tolerability are similar to those in treatment-naïve patients.


Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/administración & dosificación , Desoxicitidina/análogos & derivados , Infecciones por VIH/tratamiento farmacológico , VIH-1/inmunología , Nitrilos/administración & dosificación , Organofosfonatos/administración & dosificación , Pirimidinas/administración & dosificación , Adenina/administración & dosificación , Adenina/efectos adversos , Adulto , Anciano , Fármacos Anti-VIH/efectos adversos , Estudios de Cohortes , Desoxicitidina/administración & dosificación , Desoxicitidina/efectos adversos , Combinación de Medicamentos , Sustitución de Medicamentos , Emtricitabina , Femenino , Infecciones por VIH/inmunología , VIH-1/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Nitrilos/efectos adversos , Organofosfonatos/efectos adversos , Pirimidinas/efectos adversos , ARN Viral/efectos de los fármacos , Estudios Retrospectivos , Rilpivirina , Tenofovir , Resultado del Tratamiento , Carga Viral
3.
Infect Dis Now ; 54(2): 104863, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38340891

RESUMEN

OBJECTIVES: To evaluate current organization of infection prevention for immunocompromised patients (ICP) at a countrywide level. METHODS: Nationwide cross-sectional multicenter study based on an online survey disseminated in 2022 to physicians invested with preventive healthcare missions. RESULTS: A total of 341 physicians (96% graduates, 32% infectious disease specialists), participated in the survey, with a median age of 40 [35-51] years. On-site access to infection prevention consultations for ICP was reported by 30%, dedicated pre-travel consultations for ICPs by 29%, consultations for infection prevention in solid organ transplant candidates by 16% and return-to-work consultations for ICPs by 6%. Most participants (73%) were aware of nationwide vaccination guidelines for ICP, while 50% felt comfortable using them. Tools for infection prevention advice and ICP vaccination had been developed by 10%, while 89% would have appreciated access to tools developed by others. CONCLUSIONS: Infection prevention for ICPs remains neglected. Guidelines covering all fields of prevention for ICPs would be more than welcome.


Asunto(s)
Instituciones de Salud , Huésped Inmunocomprometido , Humanos , Adulto , Persona de Mediana Edad , Estudios Transversales , Francia , Vacunación
4.
Infect Dis Now ; 53(8): 104775, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37634659

RESUMEN

OBJECTIVES: Infectious disease (ID) advice is a major part of antimicrobial stewardship programs. The objective of this study was to assess general practitioners' (GPs)' opinions and compliance with advice given by ID hotlines. PATIENTS AND METHODS: This multicenter survey was based on the 7-day assessment of initial advice requested by GPs to a hotline set up by volunteer hospital ID teams to record advice for 3 years. The primary endpoint was the GPs' satisfaction with the advice given by ID specialists. RESULTS: Ten ID teams participated in the study and recorded 4138 requests for advice, of which 1325 requests included a proposal for antibiotic therapy and justified a follow-up call at seven days. Only 398 follow-up calls (30%) were carried out because many GPs were not reachable. GPs were very satisfied with ID hotlines: 58% considered them indispensable and 38% very useful. The recommendations provided by ID specialists were followed by GPs in more than 80% of cases. The two main motivations for GPs to call the hotline were to get quick advice (86%) and to receive help in managing a patient (76%). CONCLUSIONS: The ID telephone consultations and advice systems for GPs are highly appreciated and are effective in terms of following the recommendations.


Asunto(s)
Enfermedades Transmisibles , Médicos Generales , Humanos , Líneas Directas , Enfermedades Transmisibles/tratamiento farmacológico , Encuestas y Cuestionarios , Atención Primaria de Salud
5.
Clin Microbiol Infect ; 23(5): 334.e1-334.e8, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28017792

RESUMEN

OBJECTIVE: Staphylococcus lugdunensis is a coagulase-negative staphylococcus that displays an unusually high virulence rate close to that of Staphylococcus aureus. It also shares phenotypic properties with S. aureus and several studies found putative virulence factors. The objective of the study was to describe the clinical manifestations of S. lugdunensis infections and investigate putative virulence factors. METHOD: We conducted a prospective study from November 2013 to March 2016 at the University Hospital of Strasbourg. Putative virulence factors were investigated by clumping factor detection, screening for proteolytic activity, and sequence analysis using tandem nano-liquid chromatography-mass spectrometry. RESULTS: In total, 347 positive samples for S. lugdunensis were collected, of which 129 (37.2%) were from confirmed cases of S. lugdunensis infection. Eighty-one of these 129 patients were included in the study. Bone and prosthetic joints (PJI) were the most frequent sites of infection (n=28; 34.6%) followed by skin and soft tissues (n=23; 28.4%). We identified and purified a novel protease secreted by 50 samples (61.7%), most frequently associated with samples from deep infections and PJI (pr 0.97 and pr 0.91, respectively). Protease peptide sequencing by nano-liquid chromatography-mass spectrometry revealed a novel protease bearing 62.42% identity with ShpI, a metalloprotease secreted by Staphylococcus hyicus. CONCLUSION: This study confirms the pathogenicity of S. lugdunensis, particularly in bone and PJI. We also identified a novel metalloprotease called lugdulysin that may contribute to virulence.


Asunto(s)
Metaloproteasas/genética , Staphylococcus lugdunensis/enzimología , Factores de Virulencia/genética , Adulto , Anciano , Anciano de 80 o más Años , Secuencia de Aminoácidos , Aminoglicósidos/uso terapéutico , Secuencia de Bases , ADN Bacteriano/genética , Farmacorresistencia Bacteriana Múltiple , Eritromicina/uso terapéutico , Femenino , Fluoroquinolonas/uso terapéutico , Estudios de Seguimiento , Fosfomicina/uso terapéutico , Ácido Fusídico/uso terapéutico , Humanos , Masculino , Metaloproteasas/metabolismo , Meticilina/uso terapéutico , Persona de Mediana Edad , Ácido Fosfonoacético/uso terapéutico , Estudios Prospectivos , Análisis de Secuencia de ADN , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus lugdunensis/genética , Staphylococcus lugdunensis/patogenicidad , Vancomicina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA